ReviewJGH open : an open access journal of gastroenterology and hepatology2025
Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction.
Review in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stem Cell Therapies for Gastrointestinal and Liver Diseases: Translational Barriers, Clinical Heterogeneity, and Future Directions.Biomedicines · 2026Review
- Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioengineered tubular bile ducts are an emerging strategy in liver regenerative medicine and extrahepatic bile duct reconstruction, offering potential solutions to address biliary diseases and improve outcomes in liver transplantation. Disorders of the biliary system, such as biliary atresia, primary sclerosing cholangitis, and bile duct injury, often result in irreversible damage and cannot be adequately treated with conventional therapies. This review explores the latest advancements in the bioengineering of both intrahepatic and extrahepatic bile ducts, focusing on approaches that leverage cholangiocyte biology, stem cell technologies, and biomaterial innovations. Key cell sources, including primary cholangiocytes, induced pluripotent stem cells (iPSCs), liver progenitor cells (LPCs), and transdifferentiated hepatocytes, are discussed for their potential to generate functional bile duct epithelial cells capable of restoring biliary function. The role of biomaterials in providing structural support and promoting cellular growth and differentiation is critically examined, emphasizing synthetic and natural scaffolds, such as poly(lactic acid) (PLA) and collagen-based materials, for creating viable tubular structures. This review provides a comprehensive overview of the current progress and challenges in bioengineered bile duct tissue, focusing on the goals of enhancing liver regeneration and enabling extrahepatic bile duct reconstruction for clinical applications. Integrating cellular, biomaterial, and bioengineered strategies offers promising avenues for advancing treatments for biliary diseases and improving liver transplantation outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.